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Objectives:  To  estimate  hepatitis  A vaccine  series  initiation  and  completion  rates,  assess  time  to  vacci-
nation,  identify  missed  opportunities  for  the  hepatitis  A  vaccine  series,  and  examine  factors  associated
with  hepatitis  A  vaccine  series  initiation  and  completion.
Methods:  We  conducted  a retrospective,  observational  study  using  three  healthcare  claims  databases
separately.  The  study  population  was  comprised  of  children  born  between  years  2005  and  2009  that
were  continuously  enrolled  for  at least  three  and  a half  years  from  the  date  of birth.  Every  child  was
followed  from  date  of birth  for three  and  a half  years  for  hepatitis  A vaccination.
Results:  There  were  93,735  eligible  children  from  Clinformatics  Data  Mart, 202,513  from  MarketScan
Commercial,  and  207,545  from  MarketScan  Medicaid.  The  overall  hepatitis  A  vaccine  series initiation
rate  was  63.8–79.4%  and  completion  rate  was  45.1–66.8%  across  the three  databases.  About  62.8–90.1%
of the  children  who  never  initiated  hepatitis  A  vaccine  had  at least  one  well  visit from  1  year to  three
and  a half  years  old. Children  were  more  likely  to  initiate  and  complete  the  hepatitis  A vaccine  series if
they were  from  more  recent  birth  cohorts,  from  states  with  a  hepatitis  A vaccination  recommendation
prior  to  the  ACIP  universal  recommendation,  from  states  with  daycare/school  entry  requirements,  were
enrolled  in  an HMO  health  plan,  had  pediatricians  as  primary  providers,  had  more  doctor’s  ofﬁce/well
visits  and  received  MMR/Varicella  vaccines.
Conclusion:  In this  study,  approximately  one  in every  three  to ﬁve  children  remained  unvaccinated  against
hepatitis  A. Although  the  hepatitis  A  vaccine  series  initiation  and completion  improved  from  2005  to
2009,  vaccine  coverage  has  stabilized  in  recent  years.  It is important  for providers  to  identify  every
opportunity  for hepatitis  A vaccination  and  to  assure  that  children  get protection  from  this  vaccine-
preventable  disease.
©  2015  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. Introduction
Hepatitis A infection is caused by the hepatitis A virus (HAV)
nd is transmitted through contaminated food and water or from
erson-to-person through the fecal–oral route [1]. While most
pisodes of hepatitis A infection in young children are asymp-
omatic, infection in older children and adults generally leads to
ymptomatic illness characterized by an abrupt onset of fever,
alaise, nausea, abdominal discomfort and jaundice [1]. Althoughmproved sanitation and hygiene have reduced disease occurrence,
epatitis A outbreaks still occur, leading to signiﬁcant direct and
ndirect costs to patients and society [2–9].
∗ Corresponding author. Tel.: +1 2156524163.
E-mail address: Thomas weiss@merck.com (T. Weiss).
ttp://dx.doi.org/10.1016/j.vaccine.2015.07.065
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article 
/).license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Hepatitis A infection can be prevented through vaccination with
hepatitis A vaccine [1]. There are two  single-antigen inactivated
hepatitis A vaccines available in the US: VAQTA® manufactured by
Merck, and HAVRIX® manufactured by GlaxoSmithKline, both of
which are approved for use in children and adults. The combina-
tion vaccine TWINRIX® (GlaxoSmithKline) contains both hepatitis
A and hepatitis B antigens, but is only indicated for use in adults.
All three vaccines are highly immunogenic against HAV [10].
In 2006, the ACIP (Advisory Committee on Immunization
Practices) expanded routine hepatitis A vaccination to include chil-
dren 12 months of age irrespective of the statewide or regional
prevalence of infection, which had been the basis for prior recom-
mendations for use in children [10–12]. The ﬁrst dose of hepatitis
A vaccine is recommended for children who  are 12–23 months of
age [10]. The ACIP recommends that the two doses be separated by
6 to 18 months.
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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Initiation and completion rates of hepatitis A vaccine 2-dose
eries in US pediatric population ages 19–35 months are low
ompared to other childhood vaccines. According to the 2013
ational Immunization Survey (NIS) conducted by the CDC (Cen-
ers for Disease Control and Prevention), the estimated ≥1 dose
nd ≥2 doses hepatitis A vaccine coverage was 83.1% and 54.7%,
espectively, among children aged 19–35 months [13]. The 2-
ose coverage is well below the Healthy People 2020 goal of 85%.
our studies examined factors associated with hepatitis A vaccine
overage in different pediatric populations [14–17]. Identiﬁed fac-
ors were race/ethnicity, urban/rural environment, provider type,
chool entry requirement, and provider recommendation.
In this study, we utilized three distinct datasets to build robust
stimates across private and publicly insured children to (1) esti-
ate the hepatitis A vaccine series initiation and completion rates;
2) assess time to hepatitis A vaccination 1st dose from birth and
ime to hepatitis A vaccination 2nd dose from 1st dose; (3) identify
issed opportunities for hepatitis A vaccine series; and (4) exam-
ne factors associated with hepatitis A vaccine series initiation and
ompletion. To our knowledge, this is the ﬁrst study to use health-
are claims databases to estimate hepatitis A vaccine 2-dose series
nitiation and completion rates. When compared to cross-sectional
ssessments, claims databases afford the opportunity to monitor
ealth care utilization including receipt of immunizations such as
epatitis A vaccine over an extended period of time.
. Materials and methods
.1. Data sources
The databases used in this study included: (1) the OptumTM
linformaticsTM Data Mart database (Clinformatics Data Mart), a
roduct of OptumInsight Life Sciences, Inc.; (2) the Truven Health
arketScan® Commercial Claims and Encounters Database (Mar-
etScan Commercial); and (3) the MarketScan Medicaid Multi-State
atabase (MarketScan Medicaid).
The Clinformatics Data Mart is a database of administrative
ealth claims for members of a large national managed care com-
any afﬁliated with OptumTM covering 13 million lives annually.
he dataset includes medical claims, pharmacy claims, lab test
esults, and administrative data. Data elements include patients’
emographics, 3-digit zip code, state and region of residence,
nrollment information, date, place and charges of service, proce-
ures, diagnosis, as well as prescription drug dispensing records.
he database does not contain race or ethnicity information.
The MarketScan Commercial database includes annual medical
nd pharmacy data for approximately 45 million individuals who
re employees, spouses, and dependents covered under employer-
ponsored private health insurance. The enrollment data include
emographic information and monthly plan eligibility. Each indi-
idual in the database has a unique identiﬁer that can be used to
rack patient data across the sites of service, providers, and over
ime. Other data elements include 3-digit zip code, state and region
f residence, date, place and actual payment of service, proce-
ures, diagnosis, as well as prescription drug dispensing records.
he database does not contain race or ethnicity information.
able 1
low chart of cohort construction.
Inclusion/exclusion criteria 
Babies with birth ICD-9-CM codes between 1/1/2005 and 12/31/2009 
Continuously enrolled for 3.5 years since the identiﬁed date of birth 
Exclude babies with year of birth recorded in the database different
from year of the identiﬁed date of birth
Exclude babies with unknown gender  (2015) 6871–6877
The MarketScan Medicaid Database contains administrative
claims data for approximately 7 million Medicaid enrollees from
10 to 13 states in any data year. The database includes outpa-
tient services, inpatient services and admissions, and prescription
drug claims, as well as information on enrollment, long-term care,
and other medical care. In addition, the database includes stan-
dard demographic variables such as age and gender, and speciﬁc
variables for Medicaid populations, such as ethnicity and Medicare
eligibility. The database does not contain zip code, state or region
of residence information [18].
2.2. Study subjects
Using the three databases mentioned above, we identiﬁed
children who had birth ICD-9-CM (International Classiﬁcation of
Diseases-9th Edition-Clinical Modiﬁcation) codes between 2005
and 2009 in inpatient claims and/or outpatient claims, and were
enrolled in the plan for at least three and a half consecutive years
since date of birth. The follow-up period was decided in consider-
ation of the ACIP recommended hepatitis A vaccination schedule:
1st dose for children aged 12–23 months and interval being 6 to
18 months between 1st and 2nd dose. The longest recommended
duration is 23 + 18 = 41 months. Therefore, a follow-up period of 3.5
years (42 months) will capture this full range.
All three databases do not have date of birth and only have year
of birth in compliance with HIPAA (Health Insurance Portability
and Accountability Act). We  used the following method to identify
study subjects’ date of birth: Newly born babies were identiﬁed
by ICD-9-CM codes: Liveborn Infants according to type of birth
V30-V39. If an infant had these codes on multiple dates, the earli-
est service date was assumed to be his/her date of birth. Children
whose year of birth recorded in the database is different from the
year of the identiﬁed date of birth were excluded from the study
to avoid potential misclassiﬁcation of age. A ﬂow chart of cohort
construction can be found in Table 1.
2.3. Study variable measurements
Every child was  followed from date of birth for three and a half
years for hepatitis A vaccination. Hepatitis A vaccine was  selected
using CPT-4 (Current Procedure Terminology, 4th Edition) codes
(90633, 90634) from both inpatient and outpatient medical claims.
Hepatitis A vaccine series initiation rate was measured as per-
centage of eligible children who received at least 1 dose of hepatitis
A vaccine during the follow-up period. Hepatitis A vaccine series
completion rate was measured using two approaches: percentage
of eligible children who  received at least 2 doses of hepatitis A vac-
cine during the follow-up period (1) among all the eligible study
subjects; (2) among the eligible study subjects who  received at least
1 dose of hepatitis A vaccine.
Hepatitis A vaccine series initiation and completion rates were
stratiﬁed by the following subject characteristics where data were
available: (1) Year of birth; (2) Gender; (3) Geographic region of res-
idence (North Central, Northeast, West, South); (4) Whether states
of residence had universal hepatitis A vaccine recommendation
from 1999 (Alaska, Arizona, California, Idaho, Nevada, New Mexico,
Clinformatics
Data Mart
MarketScan
Commercial
MarketScan
Medicaid
574,787 1,489,020 1,079,642
139,046 278,164 211,024
93,748 202,513 207,545
93,735 NA NA
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60.9%, and 66.8% among the children who were born between 2005
and 2009 during three and a half years of follow-up based on Mar-
ketScan Medicaid, MarketScan Commercial, and Clinformatics Data
Mart databases, respectively. The hepatitis A vaccine completion
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klahoma, Oregon, South Dakota, Utah, Washington); (5) Whether
tates of residence have day care/school entry requirements for
epatitis A vaccine (Alaska, Arizona, Connecticut, Georgia, Idaho,
ansas, Nevada, New Mexico, North Dakota, Oklahoma, Oregon,
ennsylvania, Tennessee, Texas, Utah); (6) Ethnicity and race;
7) Health plan type (Health Maintenance Organization (HMO),
xclusive/Preferred Provider Organization (EPO & PPO), Point of
ervice (POS & POS with capitation), Other & unknown); (8)
umber of healthcare encounters during the follow-up, including
npatient hospital visits, emergency department visits, outpatient
ospital visits, doctor ofﬁce visits, and well visits; (9) Primary
rovider type, measured by type of physician visited during ≥70%
f doctor ofﬁce visits during the follow-up (Pediatrician, Pri-
ary Care Physicians (PCP), Other, No consistent provider type,
nknown); (10) Whether received MMR  (measles, mumps, rubella)
M-M-RII (CPT4 = 90707)) or Varicella-containing vaccines includ-
ng (ProQuad (CPT4 = 90710) or Varivax (CPT4 = 90716)) during the
ollow-up, as these vaccines are recommended within the same age
ange as hepatitis A vaccine.
For those children who received at least 1 dose of hepatitis
 vaccine, we assessed time (number of days) from birth to the
st dose and for those children who received at least 2 doses of
epatitis A vaccine, we assessed time (number of days) from the
st dose to the 2nd dose.
For those children who did not initiate hepatitis A vaccine, we
xamined missed opportunities for vaccination by measuring the
umber of doctor ofﬁce visits after 1 year of age until the end of
ollow-up. For those children who received hepatitis A vaccine
st dose, but did not receive the 2nd dose, we  examined missed
pportunities by measuring number of doctor ofﬁce visits after 6
onths from the 1st dose of hepatitis A vaccine until the end of the
ollow-up. Doctor ofﬁce visits were measured by three approaches:
ny doctor ofﬁce visits, well visits alone, and doctor ofﬁce visits
here children received other vaccines. These categories are not
utually exclusive.
.4. Data analysis
Descriptive statistics such as frequencies and percentages for
ategorical variables, and mean (SD) for continuous variables were
sed to describe the characteristics and study outcomes of the
ubjects. Multivariable logistic regression models were used to
nalyze the factors associated with hepatitis A vaccine series initia-
ion (yes/no) and hepatitis A vaccine series completion (yes/no) for
hose subjects who received at least one dose of hepatitis A vaccine.
orrelation between the factors was examined prior to performing
he statistical models to ensure no multicollinearity issues among
he independent variables. All statistical analyses were performed
sing SAS version 9.3 (SAS Institute, Cary, NC). A P-value less than
.05 was considered as being signiﬁcant.
. Results
After applying protocol deﬁned inclusion and exclusion criteria,
e identiﬁed the following cohort eligible children: 93,735 from
linformatics Data Mart, 202,513 from MarketScan Commercial,
nd 207,545 from MarketScan Medicaid (Table 1).
Characteristics of the three cohorts are shown in Table 2. Point
f service (POS & POS with capitation) was the dominant health
lan type in Clinformatics Data Mart (70.3%); exclusive/preferred
rovider organization (EPO & PPO) was dominant in MarketScan
ommercial (67.5%); and health maintenance organization (HMO)
as dominant in MarketScan Medicaid (74.5%). In Clinformatics
ata Mart (82.3%) and MarketScan Commercial (62.8%), the major-
ty of the study subjects had pediatricians as their primary providerFig. 1. Hepatitis A vaccine initiation rates by birth year.
type, while in MarketScan Medicaid, only 12.1% of the subjects’
primary provider type was  a pediatrician.
3.1. Series initiation
The overall hepatitis A vaccine series initiation rate was 63.8%,
74.3%, and 79.4% among the children who  were born between 2005
and 2009 during three and a half years of follow-up based on Mar-
ketScan Medicaid, MarketScan Commercial, and Clinformatics Data
Mart databases, respectively. The hepatitis A vaccine initiation rate
increased from 54.0–68.6% among the children who were born in
year 2005 to 71.2–85.5% among the children who were born in
year 2009 across the three databases (Fig. 1). For those children
who received MMR  and/or Varicella vaccine during the follow-
up, the hepatitis A vaccine series initiation rate was  much higher
(83.0–86.0%) than those who  did not receive MMR  and/or Varicella
(11.9–35.9%; Appendix 1). Additional comparisons can be found in
Appendix 1.
3.2. Series completion
The overall hepatitis A vaccine series completion rate was 45.1%,0.0%
20092008200720062005
Birth Year
Fig. 2. Hepatitis A vaccine completion rates by birth year.
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Table 2
Characteristics of the study subjects.
Variable Value Clinformatics
Data Mart
MarketScan
Commercial
MarketScan
Medicaid
(N = 93,735) (N = 202,513) (N = 207,545)
Year of Birth 2005 18.0% 13.8% 14.9%
2006 18.9% 24.0% 15.0%
2007 20.7% 21.3% 24.9%
2008 21.0% 20.5% 28.6%
2009 21.4% 20.4% 16.6%
Gender Female 48.8% 48.6% 48.7%
Male 51.2% 51.4% 51.3%
Region of United States1 North Central 27.1% 29.6% NA
Northeast 12.1% 11.6% NA
West 17.8% 9.6% NA
South 43.0% 48.6% NA
Unknown 0.0% 0.6% NA
Race  and Ethnicity2 White NA NA 50.9%
Black NA NA 34.7%
Hispanic NA NA 5.7%
Other&Unknown NA NA 8.7%
Reside in states with universal recommendation of hepatitis A
vaccine from 19991
Yes 14.0% 9.4% NA
No 86.0% 90.6% NA
Reside in states with school/day care entry requirements of
hepatitis A vaccine1
Yes 31.7% 33.8% NA
No 68.3% 66.2% NA
Health Plan Type3 HMO  8.0% 16.5% 74.5%
EPO & PPO 21.5% 67.5% 0.0%
POS & POS with capitation 70.3% 10.4% 3.9%
Other & Unknown 0.2% 5.6% 21.6%
Primary provider type during doctor ofﬁce visits4 Pediatrician 82.3% 62.8% 12.1%
PCP 8.0% 6.9% 1.4%
Other providers 0.7% 11.8% 54.3%
No consistent provider type 8.8% 13.4% 8.7%
Unknown 0.2% 5.1% 23.5%
Number of inpatient hospital visits during the follow-up period5 MEAN(SD) 0.4 (0.8) 0.2 (0.7) 0.3 (0.9)
Number  of outpatient hospital visits during the follow-up period5 MEAN(SD) 3.4 (7.9) 3.9 (8.3) 6.5 (9.9)
Number of emergency department visits during the follow-up period5 MEAN(SD) 0.4 (4.0) 0.0 (0.2) 3.7 (3.9)
Number of doctor ofﬁce visits during the follow-up period5 MEAN(SD) 29.7 (17.1) 29.8 (17.9) 21.7 (18.3)
Number of well visits6 during the follow-up period5 MEAN(SD) 9.2 (2.6) 8.8 (2.5) 4.4 (3.7)
Receipt of MMR  vaccine during the follow-up period5 Yes 88.1% 83.8% 65.1%
No 11.9% 16.2% 34.9%
Receipt of Varicella containing vaccine during the follow-up period5 Yes 87.5% 83.2% 64.1%
No 12.5% 16.8% 35.9%
1 MarketScan Medicaid does not contain variables of REGION or STATES.
2 Clinformatics Data Mart and MarketScan Commercial do not contain the variable of RACE. Where shown, categories are mutually exclusive.
3 HMO: Health Maintenance Organization; EPO: Exclusive Provider Organization; PPO: Preferred Provider Organization; POS: Point of Service.
4 PCP: Primary Care Providers, including family practice and internal medicine; Other providers: Include known provider types other than pediatricians and PCPs. For example,
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2urse  Practitioner, Medical Doctor-MD (NEC), Other Facility (NEC), etc.
The follow-up period is three and a half years since date of birth.
Well visits are a subset of doctor ofﬁce visits.
ate increased from 30.2–53.2% among the children who were born
n year 2005 to 52.3–75.0% among the children who  were born in
ear 2009 across the three databases (Fig. 2). For those children
ho received MMR  and/or Varicella vaccine during the follow-up,
he hepatitis A vaccine series completion rate was  much higher
65.9–74.1%) than those who did not receive MMR  and/or Varicella
6.2–16.3%; Appendix 2). Additional comparisons can be found in
ppendix 2.
able 3
issed opportunities.
Dataset 
Missed opportunities for 1st dose of hepatitis A vaccine1
(among those never vaccinated)
Clinformatics 
MarketScan Comme
MarketScan Medica
Missed opportunities for 2nd dose of hepatitis A vaccine2
(among those vaccinated1st dose, but not 2nd dose)
Clinformatics 
MarketScan Comme
MarketScan Medica
Number of doctor ofﬁce visits after 1 year of age until three and a half years of age.
Number of doctor ofﬁce visits after 6 months from 1st dose of hepatitis A vaccine until 3.3. Time to initiation and completion
Among those children who initiated the 2 dose hepatitis A vac-
cine series, the majority received the 1st dose between 1 year and
18 months of age (61.9–65.0%). Among those children who com-
pleted the hepatitis A vaccine 2 dose series, the majority of them
completed the 2nd dose within 6 months to 1 year after the 1st
dose (66.1–67.9%).
Had 1+ doctor
ofﬁce visit (%)
Had 1+ well
visits (%)
Had 1+ doctor ofﬁce
visit with other
vaccination (%)
96.3 90.1 78.1
rcial 97.8 89.3 73.7
id 92.2 62.8 29.0
72.9 46.7 36.4
rcial 75.3 47.8 36.2
id 71.8 31.9 21.2
three and a half years of age.
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Table  4
Factors associated with hepatitis A vaccine series initiation.
Variable Value Clinformatics Data Mart MarketScan Commercial MarketScan Medicaid
Odds ratio 95% CI Odds ratio 95% CI Odds ratio 95% CI
Year of birth 2005 Reference Reference Reference
2006 1.77 1.67–1.88 1.91 1.83–1.98 1.74 1.67–1.82
2007 2.23 2.11–2.36 2.33 2.24–2.43 1.51 1.46–1.57
2008 2.76 2.59–2.92 2.86 2.74–2.98 1.88 1.81–1.95
2009 3.22 3.03–3.43 3.53 3.38–3.68 2.57 2.47–2.68
Gender Female Reference Reference Reference
Male 0.98 0.95–1.03 1.03 1.00–1.06 1.01 0.98–1.03
Region1 North Central Reference Reference NA NA
Northeast 0.62 0.58–0.66 0.68 0.65–0.71 NA NA
West 1.41 1.29–1.55 1.77 1.64–1.89 NA NA
South 0.99 0.95–1.05 1.38 1.34–1.43 NA NA
Unknown 0.38 0.18–0.83 1.43 1.22–1.66 NA NA
Race  and Ethnicity2 White NA NA NA NA Reference
Black NA NA NA NA 1.52 1.480–1.56
Hispanic NA NA NA NA 1.05 0.997–1.11
Other & Unknown NA NA NA NA 1.14 1.088–1.19
Reside in states with universal recommendation
of hepatitis A vaccine from 19991
Yes Reference Reference NA NA
No  0.71 0.64–0.78 0.83 0.77–0.89 NA NA
Reside in states with school/day care entry
requirements of hepatitis A vaccine1
Yes Reference Reference NA NA
No  0.28 0.27–0.30 0.3 0.29–0.32 NA NA
Health Plan Type3 HMO  Reference Reference Reference
EPO/PPO 0.82 0.76–0.89 0.8 0.77–0.83 NA NA
POS/POS w/capitation 0.79 0.74–0.85 0.8 0.76–0.84 0.49 0.46–0.53
Other/Unknown 1.03 0.68–1.56 0.86 0.81–0.91 0.53 0.51–0.54
Primary provider type4 Pediatrician Reference Reference Reference
PCP 0.27 0.25–0.28 0.31 0.29–0.32 0.57 0.514–0.63
Other providers 0.66 0.54–0.80 0.72 0.69–0.75 1.98 1.917–2.03
No  consistent provider
type
0.68 0.63–0.72 0.74 0.72–0.77 0.71 0.684–0.75
Number of inpatient hospital visits during the
follow-up period5
0 Reference Reference Reference
1  0.97 0.93–1.01 1.01 0.97–1.04 0.96 0.93–0.99
2+  1.01 0.93–1.10 0.99 0.94–1.05 1.03 0.98–1.09
Number of outpatient hospital visits during the
follow-up period5
0 Reference Reference Reference
1  1.02 0.96–1.08 0.98 0.94–1.02 0.79 0.76–0.83
2  1.02 0.95–1.08 1.02 0.97–1.06 0.7 0.67–0.73
3–4  1.02 0.96–1.09 0.99 0.95–1.03 0.64 0.61–0.67
5+  1.02 0.95–1.08 1 0.96–1.04 0.65 0.62–0.67
Number of emergency department visits during
the follow-up period5
0 Reference Reference Reference
1+  1.16 1.08–1.24 0.9 0.86–0.97 1.17 1.14–1.21
Number of doctor ofﬁce visits during the
follow-up period5
0–17 Reference Reference Group Reference
18–23 1.38 1.30–1.46 1.2 1.15–1.25 1.32 1.274–1.37
24–29 1.47 1.38–1.56 1.29 1.24–1.34 1.33 1.275–1.38
30–39 1.51 1.42–1.61 1.37 1.32–1.43 1.4 1.334–1.45
40+  1.56 1.46–1.68 1.47 1.41–1.54 1.44 1.375–1.50
Number of well visits6 during the follow-up
period5
0 Reference Reference Reference
1–3 1.1 0.90–1.34 1.37 1.199–1.57 1.01 0.98–1.05
4–6  1.25 1.04–1.50 1.55 1.369–1.76 1.05 1.01–1.09
7–9  2.31 1.93–2.76 2.66 2.349–3.00 1.41 1.36–1.47
10–12 3.07 2.56–3.67 3.57 3.160–4.04 1.5 1.42–1.57
13+  2.22 1.81–2.72 2.91 2.500–3.38 0.95 0.73–1.22
Receipt of MMR  vaccine during the follow-up
period5
No Reference Reference Reference
Yes 3.24 3.01–3.49 3.36 3.20–3.53 4.93 4.72–5.15
Receipt of Varicella vaccine during the follow-up
period5
No Reference Reference Reference
Yes 4.6 4.28–4.93 4.1 3.91–4.29 3.82 3.66–3.99
1 MarketScan Medicaid does not contain variables of REGION or STATES.
2 Clinformatics Data Mart and MarketScan Commercial do not contain the variable of RACE. Where shown, categories are mutually exclusive.
3 HMO: Health Maintenance Organization; EPO: Exclusive Provider Organization; PPO: Preferred Provider Organization; POS: Point of Service.
4 PCP: Primary Care Providers, including family practice and internal medicine; Other providers: Include known provider types other than pediatricians and PCPs. For example,
N
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ourse  Practitioner, Medical Doctor-MD (NEC), Other Facility (NEC), etc.
The follow-up period is three and a half years since date of birth.
Well visits are a subset of doctor ofﬁce visits.
.4. Missed opportunities
About 62.8–90.1% of the children who never initiated hepati-
is A vaccine had at least one well visit from 1 year to three
nd a half years old (Table 3). About 31.9–47.8% of the children
ho received the 1st dose of hepatitis A vaccine but not the 2nd
ose had at least one well visit after 6 months from 1st dose
f hepatitis A vaccine until they were three and a half years
ld.3.5. Factors associated with series initiation & completion
The multivariable logistic regression models suggest that year of
birth, health plan type, primary provider type, number of doctor’s
ofﬁce visits, number of well visits, and receipt of MMR/Varicella
vaccine were independent factors associated with hepatitis A
vaccine series initiation across the three databases (Table 4). In
addition, in the commercial databases where the state of residence
is available, residing in states with universal recommendation of
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epatitis A vaccine, and residing in states with school/day care
ntry requirements of hepatitis A vaccine are also associated with
epatitis A vaccine initiation. The Medicaid database suggests that
ace and ethnicity is also associated with hepatitis A vaccine initia-
ion. Factors associated with hepatitis A vaccine initiation are also
ssociated with hepatitis A vaccine completion.
. Discussion
In this analysis of three large US claims datasets we found that
ore recent age cohorts are more likely to initiate and complete
epatitis A vaccination series. This increasing trend is likely a result
f greater acceptance of the 2006 universal ACIP recommendation.
owever, these rates still lag behind those for other routinely rec-
mmended childhood vaccines such as varicella (90.2%) and MMR
90.8%) [13].
Children were more likely to initiate and complete the vac-
ination series if they received either the MMR  vaccine or the
aricella vaccine. Living in states with universal hepatitis A vacci-
ation recommendations and school or day care requirements was
ssociated with higher initiation and completion rates. This sug-
ests that these recommendations and requirements are successful
n inducing broader uptake of hepatitis A vaccination.
When compared to other providers, pediatricians seemed much
ore likely to have patients that initiated and completed their hep-
titis A vaccination series. This may  be due to more familiarity
ith routinely vaccinating children and making strong vaccine rec-
mmendations [19–22]. Medicaid patients were consistently less
ikely to initiate and complete hepatitis A vaccination series. These
atients were also less likely to have received MMR  and varicella
accines.
Few children in the MarketScan Medicaid population had a
ediatrician as their primary provider and the majority had other
roviders as their primary provider. Perhaps either their incon-
istent care or lack of providers that provide routine vaccination
nﬂuenced vaccine uptake. Well visits were consistently associ-
ted with higher vaccine uptake. Doctor ofﬁce visits, especially well
isits are frequently a time when providers review immunization
tatus and provide an opportunity for routine vaccination.
In light of less than optimal initiation and completion of hepati-
is A vaccination, numerous missed opportunities were identiﬁed.
hese included ample physician encounters such as well visits or
ick visits, as well as vaccination with other childhood vaccines.
e were not able to identify whether the lack of a provider rec-
mmendation or parental refusal were factors for lower uptake.
esults from the logistic model found similar factors associated
ith initiation and completion rates as we did with the descriptive
nalyses.
As with all claims datasets, there are important limitations. First,
epatitis A vaccinations that were not submitted for insurance
eimbursement or received outside the network would not have
een captured. Second, we were only able to examine hepatitis
 vaccination status during the follow-up period while the child
as continuously enrolled in the health plan. This might underes-
imate vaccination coverage since children can receive hepatitis A
accination after they become 3.5 years old. Third, we used birth
CD-9-CM codes to assess study subjects’ date of birth, which left
oom for error. In addition, other factors such as whether out-of-
ocket cost-sharing is a barrier to receiving the vaccine are not
vailable in claims data. Furthermore, the study cohort consisted
f US managed care enrollees, and therefore generalization may
ot be made beyond this population, although by including the
arketScan Medicaid data the populations studied allowed us to
ompare a publicly insured population with privately insured pop-
lations. (2015) 6871–6877
Our hepatitis A vaccine series initiation results for the most
recent cohort of 2009 (81–86%) for commercial claims are simi-
lar to those found by NIS 2013 (85%). Results for the MarketScan
Medicaid population showed a 71% initiation rate, over 14% lower
than the NIS results. Our 2009 completion results (69–75%) are
higher than those found by NIS 2013 (55%). The MarketScan Med-
icaid completion percentage (52%) was more comparable with
the NIS data. However, it is important to note that we followed
patients in the claims datasets until 3.5 years (42 months) of age
whereas NIS followed patients up to 35 months of age. One strength
of our study is that we included three distinct healthcare claims
databases: Clinformatics Data Mart, MarketScan Commercial, and
MarketScan Medicaid. These three databases were analyzed sepa-
rately as opposed to blended together and complement data from
cross-sectional methodologies.
Additional research is needed to understand barriers to hep-
atitis A vaccination among both privately and publicly insured
populations and to conﬁrm the ﬁndings of this research. Also,
it is worth further understanding why  hepatitis A vaccine
series initiation and completion rates are lower in the Medicaid
database than those in the commercial claims databases. Poten-
tial factors are lack of a consistent provider, having a provider that
is not a routine vaccinator, parent attitudes, or social economics
status (SES)-related factors.
5. Conclusions
In summary, hepatitis A vaccination initiation and completion in
the United States is lower than other vaccines given at a young age.
There are missed opportunities that could be leveraged to increase
both hepatitis A vaccine initiation and completion rates. More infor-
mation is needed to better understand factors related to initiation
and completion of hepatitis A vaccination.
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